BIOMAT Database Logo BIOMAT Database Logo

Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine. 1987

R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
First Department of Internal Medicine, Nagoya University School of Medicine, Japan.

A phase I study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PLAC) was conducted in 88 patients; 36 with solid tumors and 52 with hematological malignancies, using 2 different schedules. Schedule 1 employed a single oral administration and Schedule 2, 5-day consecutive daily oral administration. In Schedule 1, the daily dose was initiated with 1 mg kg-1 which was escalated up to 24 mg kg-1 according to the modified Fibonacci's method. Side effects included nausea, vomiting and skin rashes, but myelosuppression was not seen within this dose range. In Schedule 2, the daily dose was started with 1 mg kg-1 which was escalated up to 24 mg kg-1. Major side effects were nausea, vomiting and anorexia, and mild myelosuppression was noted at 12 mg kg-1 or more. The dose-limiting toxicity was gastrointestinal toxicity, which appeared at 3.3 mg kg-1 or more and became frequent at 7 mg kg-1 or more. Pharmacokinetic study revealed that the plasma concentrations of PLAC and ara-C, obtained by the oral intake of 3.3 mg kg-1 or more of PLAC, were sufficient for these compounds to exert cytotoxic effects on various human leukemia cells in vitro. Based on these observations and plausible mechanism of action of PLAC, further clinical study should be carried out in a treatment schedule of considerably prolonged administration period with 3.3-6 mg kg-1 day-1 of PLAC.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
January 1986, Cancer chemotherapy and pharmacology,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
January 1984, Cancer research,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
January 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
January 1989, Cancer chemotherapy and pharmacology,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
[Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
June 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
January 1994, Cancer research,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells.
November 1981, Cancer research,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
[Successful treatment of chronic myelomonocytic leukemia (CMMoL) with N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PLAC)].
December 1988, [Rinsho ketsueki] The Japanese journal of clinical hematology,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Incorporation of N4-behenoyl-1-beta-D-arabinofuranosylcytosine into DNA as 1-beta-D-arabinofuranosylcytosine.
January 1988, Medical oncology and tumor pharmacotherapy,
R Ohno, and K Kimura, and K Ota, and Y Miura, and A Hoshino, and K Hattori, and M Hirano, and M Ito, and T Maekawa, and T Nakamura
Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Copied contents to your clipboard!